Intercept ‘POISE’d for PBC filings as SAEs distract investors
Positive phase III data for Intercept Pharmaceuticals Inc.’s obeticholic acid in primary biliary cirrhosis and plans for regulatory submissions in both the U.S. and Europe were overshadowed Monday as the market reacted to reports of two serious adverse events from a midstage study.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST